In all GLP-1 RAs, liraglutide (23.31%, 657 severe outcomes out of 2,819 cases) had the highest severe proportion of GLP-1 RA-associated gastrointestinal AEs, and the lowest for dulaglutide (12.29%, 1,322 severe outcomes out of 9,435 cases)
Because both substances impact blood sugar and digestion, the additive effect is the primary concern for clinicians
The moment coincided with widespread acceptance of Wegovy, Zepound, and their cohort in the mainstream
Wider access to GLP-1 medicines (glucagon-like peptide-1) for obesity and diabetes will help reduce the burden of these conditions.''Winselow Tucker, president and GM, Eli Lilly and Co (India) said: "India is entering a transformative phase in obesity and chronic weight-management care, driven by a rising disease burden, greater recognition of obesity as a chronic disease, and broader access to evidence-based prescription therapies